scholarly journals An in vitro model of coronary artery disease and the changes in intracellular calcium regulation during its progression.

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Stacey L Dineen ◽  
Mikaela L McKenney ◽  
Michael Sturek
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Intracellular Calcium ◽  
In Vitro Model ◽  
Calcium Regulation ◽  
Artery Disease ◽  
Vitro Model ◽  
Intracellular Calcium Regulation

Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro

2007 ◽  
Vol 18 (7) ◽  
pp. 523-531 ◽  
Author(s):  
Jörn F. Dopheide ◽  
Urban Sester ◽  
Axel Schlitt ◽  
Georg Horstick ◽  
Hans J. Rupprecht ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Dendritic Cells ◽  
Coronary Artery ◽  
Costimulatory Molecules ◽  
Artery Disease

In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment

Lipids ◽  
2009 ◽  
Vol 44 (10) ◽  
pp. 917-924 ◽  
Author(s):  
Ana C. Lo Prete ◽  
Clederson H. Dina ◽  
Carolina H. Azevedo ◽  
Camila G. Puk ◽  
Neuza H. M. Lopes ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Statin Treatment ◽  
Simultaneous Transfer ◽  
Artery Disease

Association of γA/γ’ Fibrinogen Levels and Coronary Artery Disease

2002 ◽  
Vol 88 (07) ◽  
pp. 26-31 ◽  
Author(s):  
Rehana Lovely ◽  
Lisa Falls ◽  
Hamid Al-Mondhiry ◽  
Charles Chambers ◽  
Gary Sexton ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Coronary Angiography ◽  
Binding Site ◽  
Factor Xiii ◽  
Blood Donors ◽  
Human Populations ◽  
Total Plasma ◽  
Artery Disease

SummaryγA/γ’ fibrinogen is a fibrinogen isoform that constitutes about 15% of total plasma fibrinogen. This isoform contains an additional binding site for zymogen factor XIII and for active thrombin, and forms fibrin clots that are resistant to fibrinolysis in vitro. Little is known about the variability of γA/γ’ fibrinogen levels in human populations, whereas total fibrinogen levels are known to increase with age and are higher in women than in men. In this report, evidence is presented that, in contrast to total fibrinogen levels, γA/γ’ fibrinogen levels showed no significant association with age or gender in a population of normal blood donors. A study of γA/γ’ fibrinogen levels in patients undergoing coronary angiography also showed that γA/γ’ fibrinogen levels were higher on average in coronary artery disease patients than in patients without coronary artery disease, and that this association was independent of total fibrinogen levels.

scholarly journals P6553Oxidative stress and plaque vulnerability: in vitro and in vivo study in patients with coronary artery disease

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
S Fiorelli ◽  
S Eligini ◽  
N Cosentino ◽  
F Fabbiocchi ◽  
G Niccoli ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
In Vivo Study ◽  
Plaque Vulnerability ◽  
Artery Disease

An in-vitro model of coronary artery stenosis: influence of stenosis morphology on velocity measurements

2002 ◽  
Author(s):  
G. Porenta ◽  
H. Baumgartner ◽  
H. Schima ◽  
W. Steffen ◽  
D. Moertl ◽  
...  
Keyword(s):  
Coronary Artery ◽  
In Vitro Model ◽  
Coronary Artery Stenosis ◽  
Artery Stenosis ◽  
Velocity Measurements ◽  
Vitro Model

scholarly journals Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease

2008 ◽  
Vol 156 (6) ◽  
pp. 1201.e1-1201.e11 ◽  
Author(s):  
Renate Schnabel ◽  
Edith Lubos ◽  
Claudia M. Messow ◽  
Christoph R. Sinning ◽  
Tanja Zeller ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antioxidant Capacity ◽  
Selenium Supplementation ◽  
Artery Disease

Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation

2012 ◽  
Vol 35 (2) ◽  
pp. 155-164 ◽  
Author(s):  
José L. Ferreiro ◽  
Masafumi Ueno ◽  
Antonio Tello-Montoliu ◽  
Salvatore D. Tomasello ◽  
Davide Capodanno ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Artery Disease

The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease

2009 ◽  
Vol 102 (07) ◽  
pp. 111-119 ◽  
Author(s):  
Motoji Kogushi ◽  
Daniela Dastros-Pitei ◽  
Marcus Flather ◽  
Deepak L. Bhatt ◽  
Victor L. Serebruany
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Healthy Volunteers ◽  
Receptor Expression ◽  
Platelet Activity ◽  
Artery Disease ◽  
In Vitro Effects ◽  
Induced Aggregation ◽  
Dose Dependent

SummaryE5555 is a potent protease-activated receptor (PAR-1) antagonist targeting the G-coupled receptor and modulating thrombinplatelet-endothelial interactions. The drug is currently being tested in phase II trials in patients with coronary artery disease (CAD) and has potential antithrombotic and anti-inflammatory benefits.We investigated the in-vitro effects of E5555 on platelet function beyond PAR-1 blockade in healthy volunteers and CAD patients treated with aspirin (ASA) with or without clopidogrel. Conventional aggregation induced by 5 µM ADP, 1 µg/ml collagen, 10 µM TRAP, whole blood aggregation with 1 µg/ml collagen, and expression of 14 intact, and TRAP-stimulated receptors by flow cytometry were utilised to assess platelet activity after preincubation with escalating concentrations of E5555 (20 ng/ml, 50 ng/ml, and 100 ng/ml) in healthy volunteers, CAD patients treated with ASA, and CAD patients treated with ASA and clopidogrel combination (n=10, for each group). E5555 inhibited a number of platelet biomarkers. Platelet inhibition was usually moderate, present already at 20 ng/ml, and was not seemingly dose-dependent without TRAP stimulation. E5555 caused 10–15% inhibition of ADP- and collagen-induced platelet aggregation in plasma, but not in whole blood.TRAP-induced aggregation was inhibited almost completely. PECAM-1, GP IIb/IIIa antigen, and activity with PAC-1, GPIb, thrombospondin, vitronectin receptor expression, and formation of platelet-monocyte aggregates were also significantly reduced by E5555.TRAP stimulation caused dose-dependent effects between 20 and 50 ng/ml E5555 doses. P-selectin, LAMP-1, LAMP, and CD40-ligand were not affected by E5555. In conclusion, E5555 in vitro moderately but significantly inhibits platelet activity beyond PAR-1 blockade. Antiplatelet potency of ASA alone, and the combination of ASA and clopidogrel may be enhanced by E5555 providing rationale for their synergistic use. Selective blockade of platelet receptors suggests unique antiplatelet properties of E5555 as a potential addition to current antithrombotic regimens.

Sign in / Sign up

Export Citation Format

Share Document